Acadia Healthcare CompanyACHC
ACHC logo
Fair Value
US$32.21
Share price21 Jul
US$28.5511.4% undervalued intrinsic discount
Loading
1Y24.35%
7D2.62%

ACHC: Operational Reforms And Board Changes Will Drive Renewed Upside

Analyst Consensus Target compiles analysts opinions to create narratives on stocks using the Analysts Consensus Price Target, forecasted revenue and earnings figures, as well as the transcripts of earnings calls.

Published
21 Feb 25
Updated
21 Jul 26
Views
412
Not Invested

Last Update 21 Jul 26

Fair value Increased 12%

ACHC: New Management And Bed Expansion Will Balance Sector And Execution Risks

Analysts have lifted their price target for Acadia Healthcare Company, with the updated fair value estimate moving from about $28.86 to $32.21. This reflects a series of recent target increases into the mid to high $30s as they factor in adjusted Q2 expectations and views on improving operational stability under new management.

Analyst Commentary

Recent research updates around Acadia Healthcare Company point to a cluster of higher fair value targets and ratings upgrades, with most commentary centering on Q2 expectations, EBITDA modeling and confidence in the newer management team.

Bullish Takeaways

  • Bullish analysts are lifting price targets into the mid to high US$30s and up to US$40, which signals increased confidence in Acadia Healthcare's ability to support higher valuation multiples if execution on recent initiatives holds.
  • Several reports highlight updated Q2 EBITDA estimates across the healthcare provider group, with Acadia Healthcare included, suggesting that earnings power assumptions are being recalibrated upward relative to prior models.
  • Analysts upgrading the stock cite belief that new management can deliver better operational stability and clearer earnings visibility, which, if realized, could reduce the perceived execution risk embedded in current valuations.
  • Bed build analysis referenced by bullish analysts points to potential upside to Street EBITDA estimates over the longer term. They view this as supporting a more constructive stance on growth and returns on invested capital.

Bearish Takeaways

  • Even with higher targets, commentary across the broader provider and hospital space continues to reference challenged hospital fundamentals and uncertainty around core earnings trajectories, which can weigh on sentiment for Acadia Healthcare as part of the same sector group.
  • Some research notes frame the current setup as "intriguing" only if upcoming results are better than feared. This implies that investors still face execution risk around Q2 delivery and how closely actual EBITDA tracks to refreshed expectations.
  • While healthcare utilization trends are described as moderating and supportive for parts of the sector, analysts also emphasize ongoing uncertainty for hospitals and related providers, which may cap how much investors are willing to pay for Acadia Healthcare until there is more consistent proof of performance under new management.
  • Upside scenarios laid out by bullish analysts, including potential EBITDA outperformance in later years, are contingent on successful bed additions and improved asset performance, and there is limited visibility today on how smoothly those plans will be executed.

What’s in the News for Acadia Healthcare Company

  • Options market activity points to expectations of a significant move in Acadia Healthcare stock, with the September 18, 2026 US$5 Call option showing some of the highest implied volatility among equity options, according to Zacks.
  • Recent analyst actions cited by Zacks include three cuts to earnings estimates for the current quarter and no upward revisions. Acadia Healthcare currently holds a Zacks Rank #3 (Hold) within the Medical, Hospital industry.
  • Acadia Healthcare has been added to several Russell indices, including the Russell 2000 Index, the Russell 2000 Value Benchmark and the Russell 2000 Dynamic Index. It has been dropped from the Russell 1000 Index, Russell 1000 Dynamic Index, Russell 1000 Value Benchmark and Russell Midcap and Russell Midcap Value benchmarks.
  • The company reaffirmed earnings guidance for the first quarter and full year 2026, with expected revenue of US$820 million to US$830 million for the quarter and US$3.37 billion to US$3.45 billion for the year. It separately guided to second quarter 2026 revenue of US$835 million to US$850 million.
  • Acadia Healthcare appointed former Chief Financial Officer David Duckworth as Interim Chief Financial Officer effective May 1, 2026, succeeding Todd Young, who is leaving to become CFO at a private equity backed animal health company. Duckworth is expected to serve at least until the ongoing search for a permanent Chief Executive Officer is completed.

Valuation Changes for Acadia Healthcare Company

  • Fair Value: The updated fair value estimate has increased slightly from $28.86 to $32.21.
  • Discount Rate: The discount rate has declined slightly from 7.99% to about 7.88%.
  • Revenue Growth: The revenue growth assumption is largely unchanged, moving marginally from about 4.92% to about 4.89%.
  • Net Profit Margin: The profit margin expectation is broadly stable, remaining at about 4.88%.
  • Future P/E: The assumed future P/E multiple has risen from about 17.22x to about 19.17x.
3 viewsusers have viewed this narrative update

Key Takeaways

  • Expansion through new facilities, joint ventures, and specialized care is set to drive continued revenue and earnings growth.
  • Technological innovation and cost management initiatives support operational efficiency, margin improvement, and increased free cash flow.
  • Shifting Medicaid dynamics, operational struggles, legal costs, and uncertainty in supplemental payments threaten revenue predictability, margin stability, and future growth prospects.

Catalysts

About Acadia Healthcare Company
    Provides behavioral healthcare services in the United States and Puerto Rico.
What are the underlying business or industry changes driving this perspective?
  • National investment in and growing societal awareness of behavioral health, as evidenced by the approval of programs like Tennessee's new Directed Payment Program, suggests sustained long-term demand growth and improved reimbursement opportunities, likely driving higher future revenue.
  • Aging population and rising commercial/Medicare patient volumes (despite current Medicaid headwinds) point to an expanding addressable market and payer diversification, which can support higher revenues and potentially stabilize or improve net margins.
  • Accelerated facility development-opening beds ahead of schedule, joint ventures with large healthcare systems, and ongoing expansion in high-demand lines (comprehensive treatment centers, specialty care)-should fuel multiyear top-line growth and operational leverage, positively impacting revenue and earnings as new facilities ramp up.
  • Proactive adoption of technology-enabled quality improvement (real-time analytics, remote monitoring, wearable safety devices) bolsters payer negotiations for value-based contracts, helps backfill underperforming facilities, and may support long-term margin improvement.
  • Lower-than-expected labor and premium cost inflation in 2025, combined with plans to moderate capital spending and reduce start-up costs in 2026, set the stage for faster free cash flow generation and potential upward momentum in net earnings and available capital for reinvestment.
Acadia Healthcare Company Earnings and Revenue Growth

Acadia Healthcare Company Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

  • Analysts are assuming Acadia Healthcare Company's revenue will grow by 4.9% annually over the next 3 years.
  • Analysts assume that profit margins will increase from -32.8% today to 4.9% in 3 years time.
  • Analysts expect earnings to reach $189.9 million (and earnings per share of $1.98) by about July 2029, up from -$1.1 billion today.
  • In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 19.4x on those 2029 earnings, up from -2.9x today. This future PE is lower than the current PE for the US Healthcare industry at 26.0x.
  • Analysts expect the number of shares outstanding to decline by 0.41% per year for the next 3 years.
  • To value all of this in today's terms, we will use a discount rate of 7.88%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?
  • Evolving Medicaid reimbursement and utilization patterns, particularly driven by increased cost pressures and changing policies, are leading to lower-than-expected Medicaid patient volumes and heightened prior authorization requirements, risking overall revenue growth and long-term margin stability if these trends persist or accelerate.
  • Ongoing operational headwinds from a group of underperforming facilities-exacerbated by negative local media coverage and referral challenges-are creating an estimated $20–$23 million annual EBITDA drag, which could result in further facility closures, lower patient days, and diminished earnings if turnaround efforts are unsuccessful.
  • Heavy reliance on substantial and potentially decreasing state Medicaid supplemental payment programs (with some states set to reduce or revise payments by 2028 under new legislation) introduces long-term uncertainty in revenue predictability and the risk of net margin compression if offsetting cost reductions are insufficient.
  • Significant start-up losses tied to rapid facility expansion (projected at $60–$65 million for 2025), coupled with recent pauses on expansion to preserve free cash flow, signal potential execution risk in managing capital allocation, which could suppress near-term net earnings and constrain future revenue growth if new facility ramps continue to lag expectations.
  • Ongoing legal and regulatory investigations, with more than $80 million spent year-to-date in legal fees and no clear end in sight, raise the risk of future settlements, reputational damage, and additional compliance costs, all of which could negatively impact future profitability and investor confidence.

Valuation

How have all the factors above been brought together to estimate a fair value?

  • The analysts have a consensus price target of $32.21 for Acadia Healthcare Company based on their expectations of its future earnings growth, profit margins and other risk factors.
  • However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $40.0, and the most bearish reporting a price target of just $13.0.
  • In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $3.9 billion, earnings will come to $189.9 million, and it would be trading on a PE ratio of 19.4x, assuming you use a discount rate of 7.9%.
  • Given the current share price of $34.43, the analyst price target of $32.21 is 6.9% lower. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
  • We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Acadia Healthcare Company?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Comments

0 comments

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Read more narratives

US$11.94
FV
139.1% overvalued intrinsic discount
5.20%
Revenue growth p.a.
60
users have viewed this narrative
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative

Fair Value vs Share Price

US$32.21
vs US$28.5511.4% undervalued intrinsic discount
PastFuture-208m4b2015201820212024202620272029Revenue US$3.9bEarnings US$189.9m
4.9%
Revenue growth
4.9%
Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on Acadia Healthcare Company

  • Fair value estimate changes
  • Narrative and analyst updates
  • Key company announcements

Company analysis

Undervalued with moderate growth potential.

Market capUS$2.8b
PB1.3x
Estimated Growth5.2%
Dividend YieldN/A
Full analysis

CEO & management

Debra Osteen
CEO
0.7yrs
CEO Tenure

Provides behavioral healthcare services in the United States and Puerto Rico.